Literature DB >> 18357580

Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.

Silvio Danese, Filippo Mocciaro, Luisa Guidi, Maria Lia Scribano, Michele Comberlato, Vito Annese, Elisabetta Colombo, Tommaso Stefanelli, Manuela Marzo, Marcello Vangeli, Raffaella Pulitano', Aldo Manca, Alessandro Armuzzi, Alberto Malesci, Cosimo Prantera, Mario Cottone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18357580     DOI： 10.1002/ibd.20426

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  4 in total

Review 1.  Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.

Authors:  Brijen Shah; Lloyd Mayer
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

2.  [Preparation of purified proteins from fresh Pheretima and their inhibitory effect against pulmonary fibrosis in mice].

Authors:  S Li; Q Yang; A Zuo; L Tian; J Huo; Y Meng; Q Tang; W Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

3.  New biologics in the management of Crohn's disease: focus on certolizumab pegol.

Authors:  Elisabetta Colombo; Fabrizio Bossa; Anna Latiano; Orazio Palmieri; Angelo Andriulli; Vito Annese
Journal:  Clin Exp Gastroenterol       Date:  2009-06-24

Review 4.  Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.

Authors:  Mahmoud Mosli; Mohammad Al Beshir; Bandar Al-Judaibi; Turki Al-Ameel; Abdulaziz Saleem; Talat Bessissow; Subrata Ghosh; Majid Almadi
Journal:  Saudi J Gastroenterol       Date:  2014 Mar-Apr       Impact factor: 2.485
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.